about
Distribution and clinical significance of hepatitis B virus genotypes in Pakistan.A simple, rapid and sensitive RP-HPLC-UV method for the simultaneous determination of sorafenib & paclitaxel in plasma and pharmaceutical dosage forms: Application to pharmacokinetic study.Green synthesis of silver nanoparticles via plant extracts: beginning a new era in cancer theranostics.Current state and prospects of the phytosynthesized colloidal gold nanoparticles and their applications in cancer theranostics.Annihilation of Leishmania by daylight responsive ZnO nanoparticles: a temporal relationship of reactive oxygen species-induced lipid and protein oxidation.Development of mannose-anchored thiolated amphotericin B nanocarriers for treatment of visceral leishmaniasis.PEG capped methotrexate silver nanoparticles for efficient anticancer activity and biocompatibility.Evaluation of prognostic factors for Peg Interferon alfa-2b plus ribavirin treatment on HCV infected patients in Pakistan.The Absence of HCV RNA and NS5A Protein in Peripheral Blood Mononuclear Cells Is a Prognostic Tool for Sustained Virological Response.Effect of biofilm formation on the excretion of Salmonella enterica serovar Typhi in feces.Modeling and analysis of innate immune responses induced by the host cells against hepatitis C virus infection.Optimum predictors of therapeutic outcome in HCV patients in Pakistan.Presence of HCV RNA in peripheral blood mononuclear cells may predict patients response to interferon and ribavirin therapy.Polymorphism of the IL28B gene (rs8099917, rs12979860) and virological response of Pakistani hepatitis C virus genotype 3 patients to pegylated interferon therapy.Metabolic syndrome is associated with poor treatment response to antiviral therapy in chronic hepatitis C genotype 3 patients.Analytical variables influencing the HCV RNA determination by TaqMan real-time PCR in routine clinical laboratory practice.Analysis of variables and interactions among variables associated with a sustained virological response to pegylated interferon alfa-2a plus ribavirin in hepatitis C virus genotype 3-infected patients.Molecular epidemiology of hepatitis C virus genotypes in different geographical regions of Punjab Province in Pakistan and a phylogenetic analysis.Evaluation of Temporal Virological Responses to Interferon-α-2b plus Ribavirin among Genotype 3a Hepatitis C Virus-Infected Patients.Selected hepatoprotective herbal medicines: Evidence from ethnomedicinal applications, animal models, and possible mechanism of actions.HPLC-DAD finger printing, antioxidant, cholinesterase, and α-glucosidase inhibitory potentials of a novel plant Olax nana.Phylogenetic analysis, structure modeling and docking study of HCV NS3 protease for the identification of potent inhibitors.A case of a patient infected with a hepatitis C virus genotype 3a multidrug resistant variant in Pakistan.Advances in nano-delivery systems for doxorubicin: an updated insight.Biosynthesized colloidal silver and gold nanoparticles as emerging leishmanicidal agents: an insight.In vitro studies on cytotoxic, DNA protecting, antibiofilm and antibacterial effects of Biogenic silver nanoparticles prepared with Bergenia ciliata rhizome extract.Wound healing applications of biogenic colloidal silver and gold nanoparticles: recent trends and future prospects.Fabrication of poly (butadiene-block-ethylene oxide) based amphiphilic polymersomes: An approach for improved oral pharmacokinetics of Sorafenib.Multifunctional theranostic applications of biocompatible green-synthesized colloidal nanoparticles.Model of the adaptive immune response system against HCV infection reveals potential immunomodulatory agents for combination therapy.Doxorubicin-loaded quaternary ammonium palmitoyl glycol chitosan polymeric nanoformulation: uptake by cells and organsCell to rodent: toxicological profiling of folate grafted thiomer enveloped nanoliposomesSynergistic Antibacterial Efficacy of Biogenic Synthesized Silver Nanoparticles using Ajuga bractosa with Standard Antibiotics: A Study Against Bacterial Pathogens
P50
Q36114474-74C9B7F9-0B09-415B-8600-FEE8632B2300Q36122613-1D685CB5-2878-416D-A759-E3232D72BEEFQ36181235-5F7EA0BE-7E6C-4AC3-A2F6-102299C6CC54Q36337528-99C0B752-662D-4388-8860-4586EEBC7D6CQ36982235-0384D9B6-DE6C-4F6D-80D1-83F20F2246D4Q38729357-EDBD480C-D51A-48A4-9F4C-CDD88B862468Q38774133-A1426DB1-FA5B-46DE-B360-C19794BC6F71Q39783539-0153A93D-EDB4-45B2-8E26-D5068C8B973BQ40057493-BA2857BA-D85C-4709-A28A-5B56A759AD1FQ40316244-5D9E7FBE-78BB-46A2-A828-386F27F45CA6Q41107347-E7BADDCA-11D3-4A54-AC38-449A2DEF6E59Q41143949-CF87D61A-3CF6-4823-B71F-6FB2628DC614Q41366464-FB2ECF0C-865F-4F9C-8C3B-F557798DEC94Q41625947-6D79DD71-EBE0-44BA-BB92-695AC7CB27EBQ42230590-517F7C99-7F4F-4163-92E0-125F15317FCCQ42977638-410997EE-917D-4170-B30B-AD3EA8E9D253Q42980821-89F83826-6D0A-483A-A231-4DE8ACE888CBQ42986576-49EC3754-39F1-4C2C-9BF3-F94D452AEBF4Q45324813-5DD00007-D9B8-4AB5-8A4F-1D0A16F6F219Q46280777-1CE4EFA9-C7E0-4FEE-AE72-285C9CB3523AQ47104848-0CE3742D-610C-40EA-99B7-5A75D417A30EQ47547033-808BE487-D562-49D6-B807-B9FEEEFD58ADQ50077326-A1585D5D-6664-46CF-AB24-BA6E6F251162Q50106753-5CE1A472-D7C0-4E40-8EBA-D0D35334C550Q50124215-CF114B8E-4655-4AAD-BC59-B8A4417A4DC2Q52581193-F7A1A32A-CFAC-465F-8AB6-03158FCC0AF5Q52626372-9BA15002-C554-4B57-8130-B0714EB4D620Q52649941-63C83A71-FC5D-4CFE-8113-8BA861F490F1Q53697638-34FD1AF9-1783-4A90-A1EF-C2FC28BD7598Q55400314-16D57B9B-E221-4AD3-A226-2EC5AC850699Q60301115-F02493A9-4EA5-42E8-92E6-038F5647B313Q61458373-BFA7A69B-1C34-4A14-BDEC-6E90B217F7E9Q90411969-EEB86BF8-A0C2-4B5F-937A-E73D55269533
P50
description
investigador
@es
researcher
@en
name
Abida Raza
@en
type
label
Abida Raza
@en
prefLabel
Abida Raza
@en
P31
P496
0000-0002-4414-1070